PT  - JOURNAL ARTICLE
AU  - Angela Y. Chang
AU  - Peter Aaby
AU  - Michael S. Avidan
AU  - Christine S. Benn
AU  - Stefano M. Bertozzi
AU  - Lawrence Blatt
AU  - Konstantin Chumakov
AU  - Shabaana A. Khader
AU  - Shyam Kottilil
AU  - Madhav Nekkar
AU  - Mihai G. Netea
AU  - Annie Sparrow
AU  - Dean T. Jamison
TI  - One vaccine to counter many diseases? Modelling the economics of oral polio vaccine against child mortality and COVID-19
AID  - 10.1101/2022.01.19.22269560
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.19.22269560
4099  - http://medrxiv.org/content/early/2022/01/21/2022.01.19.22269560.short
4100  - http://medrxiv.org/content/early/2022/01/21/2022.01.19.22269560.full
AB  - Background Recent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines’ pathogen-specific effects, but we have found only two economic evaluations of NSE. This paper starts to fill this gap by reporting economic evaluations of the NSE of oral polio vaccine (OPV) against under-five mortality and COVID-19.Methods We studied two settings: (1) reducing child mortality in a high-mortality setting (Guinea-Bissau) and (2) preventing COVID-19 in India. In the former, the intervention involves three annual campaigns in which children receive OPV incremental to routine immunization. In the latter, a susceptible-exposed-infectious-recovered model was developed to estimate the population benefits of two scenarios, in which OPV would be co-administered alongside COVID-19 vaccines. Incremental cost-effectiveness and benefit-cost ratios were modelled for ranges of intervention effectiveness estimates to supplement the headline numbers and account for heterogeneity and uncertainty.Results For child mortality, headline cost-effectiveness was $650 per child death averted. For COVID-19, assuming OPV had 20% effectiveness, incremental cost per death averted was $23,000-65,000 if it were administered simultaneously with a COVID-19 vaccine less than 200 days into a wave of the epidemic. If the COVID-19 vaccine availability were delayed, the cost per averted death would decrease to $2600-6100. Estimated benefit-to-cost ratios vary but are consistently high.Conclusion Economic evaluation suggests the potential of OPV to efficiently reduce child mortality in high mortality environments. Likewise, within a broad range of assumed effect sizes OPV could play an economically attractive role against COVID-19.Competing Interest StatementDr. Netea reports activities outside the submitted work from Trained Therapeutix Discovery; in addition, Dr. Netea has a patent Inhibitors of trained immunity licensed, and a patent Stimulators of trained immunity licensed. Dr. Kottilil reports support outside the submitted work from Regeneron Pharmaceuticals, grants from Gilead Sciences, grants from Merck Inc, grants from Arbutus Pharmaceuticals, during the conduct of the study.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors